Kronos Bio, Inc.
KRON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.04 | 0.05 | -0.04 |
| FCF Yield | -114.67% | -109.81% | -100.50% | -16.42% |
| EV / EBITDA | 0.04 | -0.30 | -0.36 | -2.98 |
| Quality | ||||
| ROIC | -82.58% | -62.64% | -47.85% | -39.11% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.70 | 0.68 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 17.44% | 13.38% | 25.11% | -157.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | 0.30 | 0.35 | 2.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.43 | -5.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,257.91 | -162.24 |